• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
    • {%itemName%} {%arrowSpan%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      As part of AbbVie’s commitment to recognising and managing Complex/Advanced Parkinson’s disease, we have developed a series of downloadable resources for healthcare professionals. These provide guidance on the role device-aided therapy plays in the management of Parkinson’s disease and where it fits in the patient treatment pathway.

      Additional insights on the management of Complex/Advanced Parkinson's disease can be found in the on-demand AbbVie promotional sponsored symposium from the Parkinson's Academy webinar in May 2021.

      Downloadable materials for HCPs

      Providing guidance on when and how to introduce conversations with patients about advanced care planning as their disease progresses.


      How considering motor, non-motor, and functional indicators of disease progression can help identify people with Complex/Advanced Parkinson’s and may support timely referral for device-aided therapies.


      An overview of the Unified Dyskinesia Rating Scale (UDysRS) and how it can be used to identify and assess the impact of dyskinesia during your patient consultations.


      Guidance on considering the window of opportunity for initiating device-aided therapy, after which patients may progress beyond eligibility.


      Parkinson’s Academy on-demand webinar

      An AbbVie promotional sponsored symposium from the Parkinson's Academy webinar May 2021, where the speakers discussed the following topics.

      • Jenny Wright: Complex/Advanced Parkinson’s: Understanding the scale of the problem.
      • Prof Nicola Pavese: Patient triage: Ensuring the timely recognition and referral for advanced therapy.
      • Dr Pamela Seenan: Choosing the right advanced therapy: Key considerations for device-aided therapy.


      1. DUODOPA (levodopa/carbidopa intestinal gel) Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/medicine/20786. Accessed August 2022.



      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on [email protected] 

      UK-DUOD-210224. Date of preparation: August 2022.